Effect of a Probiotic Strain Lactobacillus Paracasei K56 on Metabolic Symptom - a Pilot Study

NCT ID: NCT04980599

Last Updated: 2023-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-10

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent data suggest that gut microbiota can function as an environmental factor that modulates the amount of body fat and obese individuals have an altered gut microbiota.The results of previous animal studies have suggest that a probiotic strain Lactobacillus paracasei K56 have reduced high-fat diet induced obesity.

In this before-after pilot study, the participants were randomly assigned to 8 groups to compare the fat-reducing effect of the Lactobacillus paracasei K56 by continuously supplementing different product prototypes , and screen the best probiotic K56 prototype with the effect of fat reduction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Adiposity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

K56 very high dose -E1

Probiotic drink (lactobacillus paracasei K56 10\^11CFU) 350ml/d , for 60days

Group Type ACTIVE_COMPARATOR

probiotic drink with Lactobacillus paracasei K56

Intervention Type DIETARY_SUPPLEMENT

Probiotic drink (K56 10\^11CFU) 350ml/d for 60days

control -E2

maltodextrin , for 60days

Group Type PLACEBO_COMPARATOR

maltodextrin

Intervention Type DIETARY_SUPPLEMENT

maltodextrin ,for 60days

K56 high dose-E3

Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10\^10cfu) , for 60days

Group Type ACTIVE_COMPARATOR

Probiotic powder E3

Intervention Type DIETARY_SUPPLEMENT

Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;

K56 middle dose-E5

Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10\^9cfu) , for 60days

Group Type ACTIVE_COMPARATOR

Probiotic powder E5

Intervention Type DIETARY_SUPPLEMENT

probiotic powder 8g/day for 60days

K56 low dose -E7

probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10\^7cfu) , for 60days

Group Type ACTIVE_COMPARATOR

probiotic capsule E7

Intervention Type DIETARY_SUPPLEMENT

probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days

K56 middle dose-E9

probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10\^9cfu) ,for 60days

Group Type ACTIVE_COMPARATOR

probiotic capsule E9

Intervention Type DIETARY_SUPPLEMENT

probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days

K56 high dose-E1K

probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10\^10cfu), for 60days

Group Type ACTIVE_COMPARATOR

probiotic capsule E10

Intervention Type DIETARY_SUPPLEMENT

probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days

K56 very high dose-E11

probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10\^11cfu) ,for 60days

Group Type ACTIVE_COMPARATOR

probiotic capsule E11

Intervention Type DIETARY_SUPPLEMENT

probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

probiotic drink with Lactobacillus paracasei K56

Probiotic drink (K56 10\^11CFU) 350ml/d for 60days

Intervention Type DIETARY_SUPPLEMENT

maltodextrin

maltodextrin ,for 60days

Intervention Type DIETARY_SUPPLEMENT

Probiotic powder E3

Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;

Intervention Type DIETARY_SUPPLEMENT

Probiotic powder E5

probiotic powder 8g/day for 60days

Intervention Type DIETARY_SUPPLEMENT

probiotic capsule E7

probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days

Intervention Type DIETARY_SUPPLEMENT

probiotic capsule E9

probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days

Intervention Type DIETARY_SUPPLEMENT

probiotic capsule E10

probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days

Intervention Type DIETARY_SUPPLEMENT

probiotic capsule E11

probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI\>=30kg/m2,or percent of body fat(PBF) \>=25% for male, \>=30 for female.
* Age: 18 - 60 years old adults

Exclusion Criteria

* patients with severe chronic diseases (coronary heart disease, diabetes, hypertension, immune deficiency, mental disorders, tumors, liver and kidney dysfunction, etc.) and complications;irritable bowel syndrome
* History of intervention with fat-reducing drugs or health products in the past 2 months
* take weight control measures (diet, exercise, etc.) within the past month
* Those who cannot guarantee to maintain their current lifestyle during the trial period
* Those who fail to consume the tested samples as required, or fail to follow up on time, resulting in failure to determine the efficacy
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inner Mongolia Yili Industrial Group Co., Ltd

INDUSTRY

Sponsor Role collaborator

Fudan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhijun Bao

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ying Feng, Ph.D

Role: STUDY_DIRECTOR

Hua Dong Hospita Affiliated to Fu Dan University, Shanghai,China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hua Dong Hospital Affiliated to Fu Dan University

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Kadeer G, Fu W, He Y, Feng Y, Liu WH, Hung WL, Feng H, Zhao W. Effect of different doses of Lacticaseibacillus paracasei K56 on body fat and metabolic parameters in adult individuals with obesity: a pilot study. Nutr Metab (Lond). 2023 Mar 21;20(1):16. doi: 10.1186/s12986-023-00739-y.

Reference Type DERIVED
PMID: 36944956 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZBao

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Synbiotics on Obesity
NCT06578143 NOT_YET_RECRUITING PHASE2
Single Strain Probiotic
NCT05882149 UNKNOWN NA